title: Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells.
abstract: Pheochromocytoma is a rare but potentially lethal chromaffin cell tumor with currently no effective treatment. Peptide hormone receptors are frequently overexpressed on endocrine tumor cells and can be specifically targeted by various anti-tumor peptide analogs. The present study carried out on mouse pheochromocytoma cells (MPCs) and a more aggressive mouse tumor tissue-derived (MTT) cell line revealed that these cells are characterized by pronounced expression of the somatostatin receptor 2 (sst2), growth hormone-releasing hormone (GHRH) receptor and the luteinizing hormone-releasing hormone (LHRH) receptor. We further demonstrated significant anti-tumor effects mediated by cytotoxic somatostatin analogs, AN-162 and AN-238, by LHRH antagonist, Cetrorelix, by the cytotoxic LHRH analog, AN-152, and by recently developed GHRH antagonist, MIA-602, on MPC and for AN-152 and MIA-602 on MTT cells. Studies of novel anti-tumor compounds on these mouse cell lines serve as an important basis for mouse models of metastatic pheochromocytoma, which we are currently establishing.
authors.affiliation: University Hospital Carl Gustav Carus, Department of Medicine III, Dresden, Germany. Christian.Ziegler@uniklinikum-dresden.de
authors.forename: C G
authors.initials: CG
authors.lastname: Ziegler
authors.forename: M
authors.initials: M
authors.lastname: Ullrich
authors.forename: A V
authors.initials: AV
authors.lastname: Schally
authors.forename: R
authors.initials: R
authors.lastname: Bergmann
authors.forename: J
authors.initials: J
authors.lastname: Pietzsch
authors.forename: L
authors.initials: L
authors.lastname: Gebauer
authors.forename: K
authors.initials: K
authors.lastname: Gondek
authors.forename: N
authors.initials: N
authors.lastname: Qin
authors.forename: K
authors.initials: K
authors.lastname: Pacak
authors.forename: M
authors.initials: M
authors.lastname: Ehrhart-Bornstein
authors.forename: G
authors.initials: G
authors.lastname: Eisenhofer
authors.forename: S R
authors.initials: SR
authors.lastname: Bornstein
mesh_terms: D015078:2-Hydroxyphenethylamine / Q000031:analogs & derivatives / Q000494:pharmacology; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy*; D000814:Aniline Compounds / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000494:pharmacology; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D013007:Growth Hormone-Releasing Hormone / Q000037:antagonists & inhibitors; D051379:Mice; D010673:Pheochromocytoma / Q000188:drug therapy*; D011758:Pyrroles / Q000494:pharmacology; D011966:Receptors, LHRH / Q000096:biosynthesis / Q000187:drug effects / Q000378:metabolism; D018013:Receptors, Neuropeptide / Q000096:biosynthesis / Q000187:drug effects* / Q000378:metabolism; D018017:Receptors, Pituitary Hormone-Regulating Hormone / Q000096:biosynthesis / Q000187:drug effects / Q000378:metabolism; D017481:Receptors, Somatostatin / Q000096:biosynthesis / Q000187:drug effects / Q000378:metabolism; D017337:Sermorelin / Q000031:analogs & derivatives / Q000494:pharmacology; D013004:Somatostatin / Q000031:analogs & derivatives
chemical_list: C110845:AN 238; D000814:Aniline Compounds; C550121:GHRH(1-29)NH2, (PhAc-Ada)(0)-Tyr(1), Arg(2), Fpa(5,6), Ala(8), Har(9), Tyr(Me)(10), His(11), Orn(12,) Abu(15), His(20), Orn(21), Nle(27), Arg(28), Har(29)-; D011758:Pyrroles; D011966:Receptors, LHRH; D018013:Receptors, Neuropeptide; D018017:Receptors, Pituitary Hormone-Regulating Hormone; D017481:Receptors, Somatostatin; C570769:somatostatin receptor 2, mouse; C000956:N-(2-diethylaminoethyl)-N-(2-hydroxy-2-phenylethyl)-2,5-dichloroaniline; D007987:Gonadotropin-Releasing Hormone; D013004:Somatostatin; D015078:2-Hydroxyphenethylamine; D004317:Doxorubicin; D017337:Sermorelin; D013007:Growth Hormone-Releasing Hormone; C048250:somatotropin releasing hormone receptor; C062876:cetrorelix